Johnson & Johnson to buy Actelion for $30 billion, spin off R&D unit
By John Miller and John Revill | ZURICH ZURICH U.S. healthcare giant Johnson & Johnson (JNJ.N) will acquire Swiss biotech company Actelion (ATLN.S) in a $30 billion all-cash deal that includes spinning off Actelion’s research and development pipeline, the companies said on Thursday. The acquisition gives J&J access to the Swiss group’s line-up of high-price, high-margin medicines for rare diseases, helping it diversify its drug portfolio as […]